361 related articles for article (PubMed ID: 26589238)
21. Comparative effectiveness of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real-world data analysis.
Takahashi H; Asakawa K; Kosakai Y; Lee T; Rokuda M
Diabetes Obes Metab; 2024 Mar; 26(3):997-1007. PubMed ID: 38086547
[TBL] [Abstract][Full Text] [Related]
22. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
Liu Y; Hong T
Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
[TBL] [Abstract][Full Text] [Related]
23. DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1407-1417. PubMed ID: 27435042
[TBL] [Abstract][Full Text] [Related]
24. Hot Topics in Primary Care: Considerations in the Selection of Antihyperglycemic Therapy for Older Patients With Type 2 Diabetes Mellitus: A Focus on Newer Therapies.
Freeman J
J Fam Pract; 2015 Dec; 64(12 Suppl):S59-66. PubMed ID: 26845016
[TBL] [Abstract][Full Text] [Related]
25. Managing hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oral antidiabetic drugs.
Freeman JS
J Am Osteopath Assoc; 2010 Sep; 110(9):528-37. PubMed ID: 20876838
[TBL] [Abstract][Full Text] [Related]
26. Cardiorenal benefits of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes without cardiovascular and renal diseases.
Qiu M; Zhou X; Zhang M
Diabetes Obes Metab; 2022 Mar; 24(3):575-577. PubMed ID: 34729884
[No Abstract] [Full Text] [Related]
27. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin: rationale and evidences.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2016; 9(3):409-18. PubMed ID: 26732230
[TBL] [Abstract][Full Text] [Related]
28. Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong.
Mui JV; Li L; Chou OHI; Azfar N; Lee A; Hui J; Lee S; Tse G; Zhou J
Acta Diabetol; 2023 Jul; 60(7):917-927. PubMed ID: 37000300
[TBL] [Abstract][Full Text] [Related]
29. Oral combination therapy in primary care.
Kalra S; Gupta Y
J Pak Med Assoc; 2015 May; 65(5):574-5. PubMed ID: 26028398
[TBL] [Abstract][Full Text] [Related]
30. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management.
van Baar MJB; van Ruiten CC; Muskiet MHA; van Bloemendaal L; IJzerman RG; van Raalte DH
Diabetes Care; 2018 Aug; 41(8):1543-1556. PubMed ID: 30030256
[TBL] [Abstract][Full Text] [Related]
31. Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes.
Yang JY; Moon AM; Kim H; Pate V; Barritt AS; Crowley MJ; Buse JB; Stürmer T; Alexopoulos AS
J Diabetes Complications; 2020 Nov; 34(11):107706. PubMed ID: 32843283
[TBL] [Abstract][Full Text] [Related]
32. Sodium-glucose cotransporter 2 inhibitors compared with other glucose-lowering drugs in Japan: Subanalyses of the CVD-REAL 2 Study.
Kohsaka S; Takeda M; Bodegård J; Thuresson M; Kosiborod M; Yajima T; Wittbrodt E; Fenici P
J Diabetes Investig; 2021 Jan; 12(1):67-73. PubMed ID: 32530554
[TBL] [Abstract][Full Text] [Related]
33. National trends in metformin-based combination therapy of oral hypoglycaemic agents for type 2 diabetes mellitus.
Kim J; Park S; Kim H; Je NK
Eur J Clin Pharmacol; 2019 Dec; 75(12):1723-1730. PubMed ID: 31475315
[TBL] [Abstract][Full Text] [Related]
34. [Gliptin-gliflozin combination for treating type 2 diabetes].
Scheen AJ; Paquot N
Rev Med Suisse; 2016 Aug; 12(527):1384-1388. PubMed ID: 28671793
[TBL] [Abstract][Full Text] [Related]
35. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
[TBL] [Abstract][Full Text] [Related]
36. [Management of Type 2 Diabetes: a Practical Approach].
Donath M
Praxis (Bern 1994); 2016 Jun; 105(12):699-702. PubMed ID: 27269776
[TBL] [Abstract][Full Text] [Related]
37. Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm.
Wilding JP; Rajeev SP; DeFronzo RA
Diabetes Care; 2016 Aug; 39 Suppl 2():S154-64. PubMed ID: 27440828
[TBL] [Abstract][Full Text] [Related]
38. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.
Deacon CF
Nat Rev Endocrinol; 2020 Nov; 16(11):642-653. PubMed ID: 32929230
[TBL] [Abstract][Full Text] [Related]
39. Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice.
Takasu T; Hayashizaki Y; Tahara A; Kurosaki E; Takakura S
Clin Exp Pharmacol Physiol; 2015 Jan; 42(1):87-93. PubMed ID: 25311502
[TBL] [Abstract][Full Text] [Related]
40. Glucose-Lowering Agents and the Risk of Hypoglycemia: a Real-world Study.
Lyu B; Hwang YJ; Selvin E; Jameson BC; Chang AR; Grams ME; Shin JI
J Gen Intern Med; 2023 Jan; 38(1):107-114. PubMed ID: 35831767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
